Beta-Lactamase Stability of HR 756, a Novel Cephalosporin, Compared to That of Cefuroxime and Cefoxitin
AUTOR(ES)
Fu, Kwung P.
RESUMO
The stability to β-lactamase hydrolysis of HR 756, a new cephalosporin antibiotic, was compared to the β-lactamase stability of cefoxitin and cefuroxime. HR 756, cefoxitin, and cefuroxime were not hydrolyzed by Richmond type I, III, IV, and V β-lactamases. Antibacterial activity of HR 756 correlated well with resistance to β-lactamase hydrolysis except against Pseudomonas aeruginosa. HR 756, cefoxitin, and cefuroxime inhibited type I β-lactamases, but not type III, IV, or V enzymes. HR 756 was the most active inhibitor.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=352458Documentos Relacionados
- In Vitro Activity of HR 756, a New Cephalosporin, Against Neisseria gonorrhoeae
- Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum.
- Beta-lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), a novel cephalosporin.
- In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin.
- Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1.
